hVIVO PLC
LSE:HVO
hVIVO PLC
hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
hVIVO PLC provides pharmaceutical development services. The firm is engaged in testing infectious and respiratory disease vaccines and therapeutics using human challenge clinical trials. The company provides end-to-end early clinical development services to its client base, which includes global biopharma companies. The company offers a portfolio of approximately 10+ human challenge models to test a range of infectious and respiratory disease products, challenge agent manufacturing, specialist drug development, and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The company offers additional clinical field trial services, such as patient recruitment and clinical trial site services. The company runs challenge studies in from its Whitechapel quarantine clinic, and its QMB clinic with its specialized on-site virology and immunology laboratory.
Revenue Guidance Reiterated: hVIVO confirmed it is on track to deliver GBP 47 million in revenue for 2025, despite a challenging year for its core human challenge trial business.
Diversification Strategy: Management emphasized successful diversification through acquisitions (CRS and Cryostore) and the growth of new service lines beyond infectious diseases.
Profit and Cash: EBITDA was GBP 3 million for H1, with a healthy cash position of GBP 23.3 million, but both are expected to decline in the second half due to timing of payments and working capital needs.
2026–2027 Outlook: The company expects to return to growth and breakeven in 2026 and return to profitability and cash generation in 2027.
Human Challenge Trials Dip: The main business has suffered from industry headwinds like slower biotech funding and regulatory changes impacting vaccine development, but management believes this is temporary.
Order Book and Pipeline: The order book at end-June was GBP 14 million, showing growing contributions from non-human challenge trial work and improved diversification.
Cost Management: Operational efficiencies and a significant headcount reduction helped offset revenue declines.
Market Conditions: Management cited ongoing pricing pressure in pharma and regulatory uncertainty, but highlighted global demand for faster, cheaper clinical trials as a long-term tailwind.
